参考文献/References:
[1] Iung B,Baron G,Butchart EG,et al. A prospective survey of patients with valvular heart disease in Europe:the Euro Heart Survey on Valvular Heart Disease[J]. Eur Heart J,2003,24(13):1231-1243.
[2] Webster AC,Nagler EV,Morton RL,et al. Chronic kidney disease[J]. Lancet,2017,389(10075):1238-1252.
[3] Shroff GR,Bangalore S,Bhave NM,et al. Evaluation and management of aortic stenosis in chronic kidney disease:a scientific statement from the American Heart Association[J]. Circulation,2021,143(25):e1088-e1114.
[4] Samad Z,Sivak JA,Phelan M,et al. Prevalence and outcomes of left-sided valvular heart disease associated with chronic kidney disease[J]. J Am Heart Assoc,2017,6(10):e006044.
[5] Vavilis G,B?ck M,Occhino G,et al. Kidney dysfunction and the risk of developing aortic stenosis[J]. J Am Coll Cardiol,2019,73(3):305-314.
[6] Perkovic V,Hunt D,Griffin SV,et al. Accelerated progression of calcific aortic stenosis in dialysis patients[J]. Nephron Clin Pract,2003,94(2):c40-c45.
[7] Gupta JI,Gualano SK,Bhave N. Aortic stenosis in chronic kidney disease:challenges in diagnosis and treatment[J]. Heart,2022,108(16):1260-1266.
[8] Baumgartner H,Falk V,Bax JJ,et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J,2017,38(36):2739-2791.
[9] Nishimura RA,Otto CM,Bonow RO,et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2014,129(23):2440-2492.
[10] Thourani VH,Forcillo J,Beohar N,et al. Impact of preoperative chronic kidney disease in 2,531 high-risk and inoperable patients undergoing transcatheter aortic valve replacement in the PARTNER trial[J]. Ann Thorac Surg,2016,102(4):1172-1180.
[11] Patel KK,Shah SY,Arrigain S,et al. Characteristics and outcomes of patients with aortic stenosis and chronic kidney disease[J]. J Am Heart Assoc,2019,8(3):e009980.
[12] Otto CM,Prendergast B. Aortic-valve stenosis—From patients at risk to severe valve obstruction[J]. N Engl J Med,2014,371(8):744-756.
[13] Makkar RR,Fontana GP,Jilaihawi H,et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis[J]. N Engl J Med,2012,366(18):1696-1704.
[14] Go AS,Chertow GM,Fan D,et al. Chronic kidney disease and the risks of death,cardiovascular events,and hospitalization[J]. N Engl J Med,2004,351(13):1296-1305.
[15] Rattazzi M,Bertacco E,del Vecchio A,et al. Aortic valve calcification in chronic kidney disease[J]. Nephrol Dial Transplant,2013,28(12):2968-2976.
[16] London GM,Pannier B,Marchais SJ,et al. Calcification of the aortic valve in the dialyzed patient[J]. J Am Soc Nephrol,2000,11(4):778-783.
[17] Hensen LCR,Mahdiui ME,van Rosendael AR,et al. Prevalence and prognostic implications of mitral and aortic valve calcium in patients with chronic kidney disease[J]. Am J Cardiol,2018,122(10):1732-1737.
[18] Ure?a P,Malergue MC,Goldfarb B,et al. Evolutive aortic stenosis in hemodialysis patients:analysis of risk factors[J]. Nephrologie,1999,20(4):217-225.
[19] Candellier A,Bohbot Y,Pasquet A,et al. Chronic kidney disease is a key risk factor for aortic stenosis progression[J]. Nephrol Dial Transplant,2023,38(12):2776-2785.
[20] McCallum W,Testani JM. Updates in cardiorenal syndrome[J]. Med Clin North Am,2023,107(4):763-780.
[21] Yamamoto M,Hayashida K,Mouillet G,et al. Prognostic value of chronic kidney disease after transcatheter aortic valve implantation[J]. J Am Coll Cardiol,2013,62(10):869-877.
[22] Dumonteil N,van der Boon RM,Tchetche D,et al. Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation:a Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy[J]. Am Heart J,2013,165(5):752-760.
[23] Allende R,Webb JG,Munoz-Garcia AJ,et al. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation:insights on clinical outcomes and prognostic markers from a large cohort of patients[J]. Eur Heart J,2014,35(38):2685-2696.
[24] Ferro CJ,Chue CD,de Belder MA,et al. Impact of renal function on survival after transcatheter aortic valve implantation (TAVI):an analysis of the UK TAVI registry[J]. Heart,2015,101(7):546-552.
[25] D’errigo P,Moretti C,D’ascenzo F,et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in patients with chronic kidney disease stages 3b to 5[J]. Ann Thorac Surg,2016,102(2):540-547.
[26] Garcia S,Cubeddu RJ,Hahn RT,et al. 5-Year outcomes comparing surgical versus transcatheter aortic valve replacement in patients with chronic kidney disease[J]. JACC Cardiovasc Interv,2021,14(18):1995-2005.
[27] Galper BZ,Goldsweig AM,Bhatt DL. TAVR and the kidney:is this the beginning of a beautiful friendship?[J]. J Am Coll Cardiol,2020,76(12):1422-1424.
[28] Steinmetz T,Witberg G,Chagnac A,et al. Transcatheter aortic valve implantation versus conservative treatment in chronic kidney disease patients[J]. EuroIntervention,2018,14(5):e503-e510.
[29] Cubeddu RJ,Asher CR,Lowry AM,et al. Impact of transcatheter aortic valve replacement on severity of chronic kidney disease[J]. J Am Coll Cardiol,2020,76(12):1410-1421.
[30] Nguyen TC,Babaliaros VC,Razavi SA,et al. Impact of varying degrees of renal dysfunction on transcatheter and surgical aortic valve replacement[J]. J Thorac Cardiovasc Surg,2013,146(6):1399-1406.
[31] Aregger F,Wenaweser P,Hellige GJ,et al. Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement[J]. Nephrol Dial Transplant,2009,24(7):2175-2179.
[32] Makki N,Lilly SM. Advanced chronic kidney disease:relationship to outcomes post-TAVR,a meta-analysis[J]. Clin Cardiol,2018,41(8):1091-1096.
[33] Hensey M,Murdoch DJ,Sathananthan J,et al. Impact of chronic kidney disease on decision making and management in transcatheter aortic valve interventions[J]. Can J Cardiol,2019,35(9):1188-1194.
[34] Mehran R,Dangas GD,Weisbord SD. Contrast-associated acute kidney injury[J]. N Engl J Med,2019,380(22):2146-2155.
[35] Najjar M,Salna M,George I. Acute kidney injury after aortic valve replacement:incidence,risk factors and outcomes[J]. Expert Rev Cardiovasc Ther,2015,13(3):301-316.
[36] Kappetein AP,Head SJ,Généreux P,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation:the Valve Academic Research Consortium-2 consensus document[J]. Eur Heart J,2012,33(19):2403-2418.
[37] Owen RJ,Hiremath S,Myers A,et al. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy:update 2012[J]. Can Assoc Radiol J,2014,65(2):96-105.
[38] Thongprayoon C,Cheungpasitporn W,Srivali N,et al. AKI after transcatheter or surgical aortic valve replacement[J]. J Am Soc Nephrol,2016,27(6):1854-1860.
[39] Villablanca PA,Mathew V,Thourani VH,et al. A meta-analysis and meta-regression of long-term outcomes of transcatheter versus surgical aortic valve replacement for severe aortic stenosis[J]. Int J Cardiol,2016,225:234-243.
[40] Crowhurst JA,Savage M,Subban V,et al. Factors contributing to acute kidney injury and the impact on mortality in patients undergoing transcatheter aortic valve replacement[J]. Heart Lung Circ,2016,25(3):282-289.
[41] Aoun J,Nicolas D,Brown JR,et al. Maximum allowable contrast dose and prevention of acute kidney injury following cardiovascular procedures[J]. Curr Opin Nephrol Hypertens,2018,27(2):121-129.
[42] Bagur R,Webb JG,Nietlispach F,et al. Acute kidney injury following transcatheter aortic valve implantation:predictive factors,prognostic value,and comparison with surgical aortic valve replacement[J]. Eur Heart J,2010,31(7):865-874.
[43] Barbash IM,Ben-Dor I,Dvir D,et al. Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement[J]. Am Heart J,2012,163(6):1031-1036.
[44] Lunardi M,Mylotte D. Surgical or transcatheter aortic valve replacement in patients with chronic kidney disease:does renal impairment matter?[J]. JACC Cardiovasc Interv,2021,14(18):2006-2009.
[45] Auffret V,Regueiro A,del Trigo M,et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve?replacement[J]. J Am Coll Cardiol,2016,68(7):673-684.
[46] Vellanki K,Bansal VK. Neurologic complications of chronic kidney disease[J]. Curr Neurol Neurosci Rep,2015,15(8):50.
[47] Molnar AO,Bota SE,Garg AX,et al. The risk of major hemorrhage with CKD[J]. J Am Soc Nephrol,2016,27(9):2825-2832.
[48] Masson P,Webster AC,Hong M,et al. Chronic kidney disease and the risk of stroke:a systematic review and meta-analysis[J]. Nephrol Dial Transplant,2015,30(7):1162-1169.
相似文献/References:
[1]于海波,综述,梁延春,等.经导管主动脉瓣膜置换术后房室传导阻滞的预警[J].心血管病学进展,2016,(4):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
YU Haibo,LIANG Yanchun.Predicting Factors of Atrioventricular Block after Transcatheter
Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2016,(8):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
[2]谢晓川,饶莉.经导管主动脉瓣植入术临床研究进展[J].心血管病学进展,2015,(6):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
XIE Xiaochuan,RAO Li.Clinical Research Progress in Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(8):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
[3]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(8):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[4]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(8):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[5]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[6]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[7]夏平.“8+2”心电图临床价值的研究进展夏平[J].心血管病学进展,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
XIA Ping.Clinical Value of 8 Plus 2 ECG[J].Advances in Cardiovascular Diseases,2021,(8):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
[8]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[9]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(8):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[10]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]